Chondropeptix Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
4
Chondropeptix General Information
Description
Operator of a biotechnology company intended to treat cartilage injuries and defects of patients. The company specializes in the research and development of peptide-based drugs to stimulate cartilage regeneration in joints, enabling patients to efficiently recover from cartilage defects without any surgery.
Contact Information
Website
www.chondropeptix.comCorporate Office
- Oxfordlaan 70
- 6229 EV Maastricht
- Netherlands
Corporate Office
- Oxfordlaan 70
- 6229 EV Maastricht
- Netherlands
Chondropeptix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 01-Nov-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 05-Jul-2019 | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Chondropeptix Patents
Chondropeptix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3442559-B1 | Bmp-7 derived peptides for use in a method of the treatment or prevention of osteoarthritis | Active | 13-Apr-2016 | ||
| EP-3442559-C0 | Bmp-7 derived peptides for use in a method of the treatment or prevention of osteoarthritis | Active | 13-Apr-2016 | ||
| ES-2837003-T3 | Bmp-7 derived peptides for use in the treatment of osteoarthritis | Active | 13-Apr-2016 | ||
| EP-3442558-B1 | Bmp-7 derived peptides for use in the treatment of osteoarthritis. | Active | 13-Apr-2016 | ||
| EP-3442559-A1 | Method for the treatment or prevention of osteoarthritis | Active | 13-Apr-2016 | A61K38/1875 |
Chondropeptix Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Particon | PE/Buyout | Minority | ||
| Limburg Business Development Fund | Venture Capital | Minority | ||
| ReumaNederland | Corporation | Minority | ||
| Maastricht University | University | Minority |
Chondropeptix FAQs
-
When was Chondropeptix founded?
Chondropeptix was founded in 2018.
-
Where is Chondropeptix headquartered?
Chondropeptix is headquartered in Maastricht, Netherlands.
-
What industry is Chondropeptix in?
Chondropeptix’s primary industry is Drug Discovery.
-
Is Chondropeptix a private or public company?
Chondropeptix is a Private company.
-
What is Chondropeptix’s current revenue?
The current revenue for Chondropeptix is .
-
How much funding has Chondropeptix raised over time?
Chondropeptix has raised $1.1M.
-
Who are Chondropeptix’s investors?
Particon, Limburg Business Development Fund, ReumaNederland, and Maastricht University have invested in Chondropeptix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process